Kuros Biosciences AG (CSBTF)
USD 32.4
(3.09%)
USD 32.4
(3.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -13.19 Million CHF | 33.77% |
| 2022 | -13.44 Million CHF | -53.37% |
| 2021 | -8.76 Million CHF | 24.93% |
| 2020 | -11.67 Million CHF | -2.52% |
| 2019 | -11.39 Million CHF | 17.01% |
| 2018 | -13.72 Million CHF | 15.49% |
| 2017 | -16.24 Million CHF | 23.91% |
| 2016 | -21.34 Million CHF | -3363.91% |
| 2015 | 654 Thousand CHF | 103.45% |
| 2014 | -18.93 Million CHF | 18.61% |
| 2013 | -23.26 Million CHF | -72.4% |
| 2012 | -13.49 Million CHF | 31.55% |
| 2011 | -19.71 Million CHF | -410.2% |
| 2010 | -3.86 Million CHF | 85.81% |
| 2009 | -27.23 Million CHF | -14.05% |
| 2008 | -23.88 Million CHF | -187.75% |
| 2007 | -8.3 Million CHF | 76.35% |
| 2006 | -35.09 Million CHF | -19.7% |
| 2005 | -29.31 Million CHF | -21.26% |
| 2004 | -24.17 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -279.5 Thousand CHF | 93.42% |
| 2024 Q2 | -279.5 Thousand CHF | 0.0% |
| 2023 FY | -8.9 Million CHF | 33.77% |
| 2023 Q2 | -4.65 Million CHF | -105.7% |
| 2023 Q1 | -2.26 Million CHF | 70.63% |
| 2023 Q4 | -4.24 Million CHF | -105.77% |
| 2023 Q3 | -2.06 Million CHF | 55.69% |
| 2022 Q1 | -1.19 Million CHF | 83.94% |
| 2022 FY | -13.44 Million CHF | -53.37% |
| 2022 Q4 | -7.71 Million CHF | -106.56% |
| 2022 Q3 | -3.73 Million CHF | -49.5% |
| 2022 Q2 | -2.49 Million CHF | -109.83% |
| 2021 FY | -8.76 Million CHF | 24.93% |
| 2021 Q3 | -3.65 Million CHF | -133.5% |
| 2021 Q4 | -7.4 Million CHF | -102.46% |
| 2021 Q2 | -1.56 Million CHF | -116.29% |
| 2021 Q1 | -724.5 Thousand CHF | 86.82% |
| 2020 Q3 | -2.7 Million CHF | 58.28% |
| 2020 Q4 | -5.49 Million CHF | -102.95% |
| 2020 Q2 | -6.49 Million CHF | -103.83% |
| 2020 FY | -11.67 Million CHF | -2.52% |
| 2020 Q1 | -3.18 Million CHF | 48.06% |
| 2019 Q3 | -3.01 Million CHF | 45.54% |
| 2019 FY | -11.39 Million CHF | 17.01% |
| 2019 Q4 | -6.13 Million CHF | -103.25% |
| 2019 Q2 | -5.54 Million CHF | -106.79% |
| 2019 Q1 | -2.67 Million CHF | 32.52% |
| 2018 Q4 | -3.97 Million CHF | 0.0% |
| 2018 Q2 | -2.89 Million CHF | 0.0% |
| 2018 Q3 | -3.97 Million CHF | -37.2% |
| 2018 FY | -13.72 Million CHF | 15.49% |
| 2018 Q1 | -2.89 Million CHF | 37.85% |
| 2017 Q1 | -3.46 Million CHF | 6.87% |
| 2017 Q2 | -3.46 Million CHF | 0.0% |
| 2017 Q3 | -4.65 Million CHF | -34.32% |
| 2017 Q4 | -4.65 Million CHF | 0.0% |
| 2017 FY | -16.24 Million CHF | 23.91% |
| 2016 Q1 | -6.95 Million CHF | -344.04% |
| 2016 Q2 | -6.95 Million CHF | 0.0% |
| 2016 FY | -21.34 Million CHF | -3363.91% |
| 2016 Q3 | -3.72 Million CHF | 46.46% |
| 2016 Q4 | -3.72 Million CHF | 0.0% |
| 2015 Q1 | -545.5 Thousand CHF | 0.0% |
| 2015 Q4 | -1.56 Million CHF | 0.0% |
| 2015 FY | 654 Thousand CHF | 103.45% |
| 2015 Q2 | -545.5 Thousand CHF | 0.0% |
| 2015 Q3 | -1.56 Million CHF | -186.98% |
| 2014 FY | -18.93 Million CHF | 18.61% |
| 2013 Q4 | -7.48 Million CHF | -29.62% |
| 2013 Q2 | -6.28 Million CHF | -68.68% |
| 2013 Q1 | -3.72 Million CHF | 25.55% |
| 2013 Q3 | -5.77 Million CHF | 8.03% |
| 2013 FY | -23.26 Million CHF | -72.4% |
| 2012 Q2 | -1.82 Million CHF | 33.24% |
| 2012 Q4 | -5 Million CHF | -26.99% |
| 2012 Q3 | -3.93 Million CHF | -115.9% |
| 2012 Q1 | -2.73 Million CHF | 21.27% |
| 2012 FY | -13.49 Million CHF | 31.55% |
| 2011 Q4 | -3.47 Million CHF | 50.25% |
| 2011 Q2 | -4.33 Million CHF | 12.14% |
| 2011 Q1 | -4.93 Million CHF | 8.07% |
| 2011 Q3 | -6.97 Million CHF | -60.9% |
| 2011 FY | -19.71 Million CHF | -410.2% |
| 2010 Q1 | -6.67 Million CHF | -10.06% |
| 2010 FY | -3.86 Million CHF | 85.81% |
| 2010 Q4 | -5.36 Million CHF | 2.91% |
| 2010 Q3 | -5.52 Million CHF | -140.34% |
| 2010 Q2 | 13.7 Million CHF | 305.38% |
| 2009 Q4 | -6.06 Million CHF | -13.5% |
| 2009 FY | -27.23 Million CHF | -14.05% |
| 2009 Q1 | -10.73 Million CHF | 0.0% |
| 2009 Q2 | -5.1 Million CHF | 52.5% |
| 2009 Q3 | -5.34 Million CHF | -4.73% |
| 2008 FY | -23.88 Million CHF | -187.75% |
| 2007 FY | -8.3 Million CHF | 76.35% |
| 2006 FY | -35.09 Million CHF | -19.7% |
| 2005 FY | -29.31 Million CHF | -21.26% |
| 2004 FY | -24.17 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Agentix Corp. | -1.37 Million USD | -861.687% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -161.513% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -316.378% |
| Biomind Labs Inc. | -1 Million USD | -1206.652% |
| ContraFect Corporation | -56.88 Million USD | 76.811% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1316.393% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -402.07% |
| CSL Limited | 3.7 Billion USD | 100.356% |
| CytoDyn Inc. | -18.05 Million USD | 26.947% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 26.083% |
| GB Sciences, Inc. | -1.42 Million USD | -828.681% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -607.585% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -287.433% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -3286.298% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -5894.238% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 76.234% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3075.13% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -758.827% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1820.373% |
| Skye Bioscience, Inc. | -13.67 Million USD | 3.509% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 116.117% |
| SQZ Biotechnologies Company | -75.82 Million USD | 82.602% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -564.09% |
| Zenith Capital Corp. | -8.94 Million USD | -47.512% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 81.623% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -362.795% |
| Mesoblast Limited | -84.14 Million USD | 84.323% |
| Marizyme, Inc. | -34.08 Million USD | 61.298% |
| Genus plc | 6.4 Million USD | 306.125% |
| Pharming Group N.V. | -4.87 Million USD | -170.353% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -57.988% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -840.948% |
| IMV Inc. | -38.67 Million USD | 65.887% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -379.563% |
| MultiCell Technologies, Inc. | -722.81 USD | -1824999.265% |
| ONE Bio Corp. | 13.68 Million USD | 196.422% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 77.637% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 472.655% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -354.701% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -98.435% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -43943.803% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 16.873% |
| Alpha Cognition Inc. | -9.7 Million USD | -35.922% |
| Enzolytics Inc. | -2.14 Million USD | -513.924% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 96.896% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1163.602% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -351.867% |
| Genscript Biotech Corporation | -415.79 Million USD | 96.827% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 368.413% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -4940.386% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -437.283% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -7591.7% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -558.035% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 235.407% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -189.633% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -252.123% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1240.578% |
| EV Biologics, Inc. | -483.06 Thousand USD | -2630.912% |
| Q BioMed Inc. | -3.44 Million USD | -282.863% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -950.318% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 76.002% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -69.585% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -582.6% |
| HST Global, Inc. | -140.9 Thousand USD | -9262.203% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -887.846% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1072.72% |
| Halberd Corporation | -75.05 Thousand USD | -17477.615% |
| Resverlogix Corp. | -12.74 Million USD | -3.475% |
| Cell Source, Inc. | -4.32 Million USD | -204.993% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -735.278% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 297.105% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -75624.7% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -434.791% |
| Kadimastem Ltd | -3.04 Million USD | -333.912% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -211.249% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -7168.92% |
| LadRx Corporation | -3.82 Million USD | -245.013% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1820.373% |
| Affymax, Inc. | -15.04 Million USD | 12.322% |
| Itoco Inc. | -919.14 Thousand USD | -1335.255% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1078.91% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2278.866% |
| International Stem Cell Corporation | -663 Thousand USD | -1889.744% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -245.327% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -52311.601% |
| Qrons Inc. | -643.67 Thousand USD | -1949.475% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2236.013% |
| SYBLEU INC | -149.18 Thousand USD | -8743.008% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -491.602% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1886.747% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -626.304% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -24960.79% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -64757.424% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 63.624% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -715.328% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1692.793% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -324.044% |
| Neutra Corp. | -229.48 Thousand USD | -5648.499% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 24.785% |
| PureTech Health plc | -146.19 Million USD | 90.977% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 38.617% |
| IXICO plc | -1.43 Million USD | -818.024% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -38.995% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 89.17% |
| CSL Limited | 3.81 Billion USD | 100.346% |
| Cellectis S.A. | -108.85 Million USD | 87.881% |